Dual PPAR Agonist Aromatic Compound for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) lack effective pharmacological interventions that can address the underlying metabolic and inflammatory issues, particularly in regulating fatty acid transport and gluconeogenesis, with existing PPAR agonists showing limitations in safety and efficacy.
Innovation Solution
A novel aromatic compound with a 2-phenoxyacetic acid structure acts as a dual agonist for PPAR α and δ, offering improved physicochemical, pharmacokinetic properties, and safety profile, including enhanced bioavailability and reduced toxicity, thereby effectively activating PPAR in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PPAR agonists are used for treating NAFLD and NASH, then some therapeutic effect is achieved, but safety issues and limited efficacy persist
Solution Approach 1:
The patent modifies the chemical structure parameters of PPAR agonists by introducing specific substituents (R1-R6 groups) at defined positions on the core aromatic ring structure. This structural parameter optimization enables selective activation of PPARα and PPARδ while minimizing off-target effects and toxicity, thereby improving the safety profile compared to existing agonists
2Reliability
If existing PPAR agonists are used, then some metabolic regulation is achieved, but efficacy in addressing underlying metabolic and inflammatory issues is limited
Solution Approach 1:
The patent designs a dual agonist compound that simultaneously activates both PPARα and PPARδ receptors through a single molecular structure. This multi-functionality allows the compound to address multiple pathogenic mechanisms in NASH including fatty acid transport, β-oxidation, glucose utilization, and inflammatory response, thereby achieving superior efficacy compared to single-receptor agonists
3Adaptability or versatility
If a dual agonist for PPARα and PPARδ is developed, then comprehensive metabolic regulation is achieved, but physicochemical properties and pharmacokinetic profile need optimization
Solution Approach 1:
The patent introduces specific local substitutions (R1-R6 groups) at defined positions on the aromatic core structure to optimize local molecular properties. These localized modifications tune the compound's solubility, stability, and pharmacokinetic characteristics while preserving the dual agonist activity, achieving a balance between metabolic regulation capability and physicochemical stability
Data Source
AI summary
The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.